Director Rothbaum Reports a $26.5 Million IOVA Purchase

September 18, 2023

From the Desk of Steve Strazza

The most significant insider purchase on today’s list comes from Wayne P. Rothbaum, director of Iovance Biotherapeutics $IOVA.

Rothbaum declared a $26.5 million IOVA purchase in a Form 4 filing.

Great Point Partners LLC filed a 13G for UroGen Pharma Ltd $URGN revealing an initial stake of 8.51%.

Here’s The Hot List, with data through September 15, 2023:

In another Form 4, director Jonathan Kraft reported a purchase of $507,650 in TKO Group Holdings $TKO.

There was also insider activity in ChargePoint Holdings $CHPT and Victoria’s Secret & Co $VSCO.

In the options market, there was bullish flow in ADT Inc $ADT, Nordic American Tankers Limited $NAT, and Viking Therapeutics Inc $VKTX.

Stay tuned. We’ll be back on Tuesday with more insider activity.

Filed Under: